ORGANIC
LETTERS
2008
Vol. 10, No. 2
193-195
Highly Efficient Asymmetric Synthesis
of Fluvirucinine A1 via Zr-Catalyzed
Asymmetric Carboalumination of
Alkenes (ZACA)−Lipase-Catalyzed
Acetylation Tandem Process
Bo Liang and Ei-ichi Negishi*
Herbert C. Brown Laboratories of Chemistry, Purdue UniVersity, 560 OVal DriVe,
West Lafayette, Indiana 47907-2084
Received October 20, 2007
ABSTRACT
ZACA
1-ol to provide the corresponding enantiomerically pure (R)-2-ethyl-1-alkanols. Either (R)-5 or (R)-6 was converted to 3 in seven steps. The
other fragment 4 was synthesized in nine steps from ( )-(S)-citronellol. Conversion of 3 and 4 into 99% pure fluvirucinine A1 was achieved in
four steps via amidation ring closing metathesis, the overall yield in the longest linear sequence being 34% (13 steps).
−lipase-catalyzed acetylation tandem process has been shown to proceed satisfactorily with either TBS-protected 4-penten-1-ol or 3-buten-
−
−
Fluvirucinine A1 (1a) is an aglycone of fluvirucin A1 (1b),
a member of antibiotics isolated from the fermentation broth
of unidentified actinomycete strains exhibiting considerable
inhibitory activity against influenza A virus.1 It has recently
been synthesized by Suh2 in 22 linear steps in about 3%
overall yield. Our recent development of the ZACA-lipase-
catalyzed acetylation tandem process3 permitting efficient
and selective syntheses of enantiomerically pure 2-methyl-
1-alkanols prompted us to see if this tandem process would
be readily adaptable to the synthesis of 2-alkyl-1-alkanols,
where the 2-alkyl group is ethyl or a higher primary alkyl
group. If so, a convergent and highly efficient synthesis of
1a via 2, which in turn should be obtained from 3 and 4, as
outlined in a retrosynthetic analysis shown in Scheme 1
would be feasible.
The first crucial task of devising efficient and enantiose-
lective routes to 3 was achieved in two similar manners, as
summarized in Scheme 2. In Route I, commercially available
4-penten-1-ol was protected with TBSCl and imidazole in
98% yield and subjected to the ZACA reaction4-6 with Et3-
Al (2 equiv), isobutylaluminoxane (IBAO, 1 equiv) generated
(1) (a) Naruse, N.; Tenmyo, O.; Kawauo, K.; Tomita, K.; Ohgusa, N.;
Miyaki, T.; Konishi, M.; Oki, T. J. Antibiot. 1991, 44, 733-740. (b) Naruse,
N.; Tsuno, T.; Sawada, Y.; Konishi, M.; Oki, T. J. Antibiot. 1991, 44, 741-
755. (c) Naruse, N.; Konishi, M.; Oki, T.; Inouye, Y.; Kakisawa, H. J.
Antibiot. 1991, 44, 756-761. (d) Tomita, K.; Oda, N.; Hoshino, Y.; Ohgusa,
N.; Chikazawa, H. J. Antibiot. 1991, 44, 940-948.
(2) Suh, Y.-G.; Kim, S.-A.; Jung, J.-K.; Shin, D.-Y.; Min, K.-H.; Koo,
B.-A.; Kim, H.-S. Angew. Chem., Int. Ed. 1999, 38, 3545-3547.
(3) Huang, Z.; Tan, Z.; Novak, T.; Zhu, G.; Negishi, E. AdV. Synth. Catal.
2007, 349, 539-545. ZACA stands for Zr-catalyzed asymmetric carboalu-
mination of alkenes.
(4) (a) Kondakov, D.; Negishi, E. J. Am. Chem. Soc. 1995, 117, 10771-
10772. (b) Kondakov, D.; Negishi, E. J. Am. Chem. Soc. 1996, 118, 1577-
1578. (c) Huo, S.; Negishi, E. Org. Lett. 2001, 3, 3253-3256.
(5) (a) For the use of IBAO as a promotor, see: Huo, S.; Shi, J.; Negishi,
E. Angew. Chem., Int. Ed. 2002, 41, 2141-2143. (b) For a seminal
contribution on the use of promotors, such as methylaluminoxane (MAO)
and H2O, see: Wipf, P.; Ribe, S. Org. Lett. 2000, 2, 1713-1716.
10.1021/ol702272d CCC: $40.75
© 2008 American Chemical Society
Published on Web 12/13/2007